Urol. praxi, 2014; 15(4): 182-184

Xp 11.2 translocation renal cell carcinoma

MUDr.Zuzana Kováčová-Majerová, FEBU, MUDr.Radomír Zachoval, Ph.D., Dr.h.c., MUDr.Yaroslav Andriychuk
Urologické oddělení nemocnice Třebíč

A case report of a young patient with an image of a renal colic, with a finding of a huge renal tumour. A metastasis in a regional lymph

node was present at time of diagnosis. The patient has undergone a radical nephrectomy and lymphadenectomy with a histological

finding of a renal cell carcinoma with a Xp 11,2 translocation, pT2a N1 Mo G3. Patient has started a target therapy as a part of a clinical

trial and he is without signs of metastases.

Keywords: Xp 11,2 translocation renal cell carcinoma, target therapy

Published: October 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kováčová-Majerová Z, Zachoval R, Andriychuk Y. Xp 11.2 translocation renal cell carcinoma. Urol. praxi. 2014;15(4):182-184.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr; 61(2): 69-90. Go to original source... Go to PubMed...
    2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010 Mar; 46(4): 765-781. Go to original source... Go to PubMed...
    3. Landis SH, Murray T, Bolden S, et al. Cancer statistics: 1999. CA Cancer J Clin, 1999; 49: 8-31. Go to original source... Go to PubMed...
    4. Novotvary 2007 ČR. ÚZIS ČR 2010. www.svod.cz.
    5. Kawaciuk I, Hyršl L, Dušek P, Jarolím L, et al. Rozměr nádoru, staging a grading malignity v prognóze karcinomu ledviny. Ces. Urol 2005; 9(3): 42.
    6. Lonser RR, Glenn GM, Walther MM, Chew EY, Libutti SK, Linehan WM, et al. Von Hippel-Lindau disease. Lancet 2003; 361: 2059-2067. Go to original source... Go to PubMed...
    7. Branžovský J, Martínek P, Baulet K. Využití molekulární genetiky v diferenciální diagnostice nádorů ledvin. Ces Urol 2012; 16(4): 214-221.
    8. Camparo P, Vailiu V, Molinie V, et al. Renal translocation carcinomas. Clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg pathol 2008; 35: 656-670. Go to original source... Go to PubMed...
    9. Salles PGO, Soto M jr. Kidney carcinoma associated with Xp11.2 translocation/TFE3 (ASPL-TFE3) gen vision. Int Braz J Urol 2005; 31: 251-255. Go to original source... Go to PubMed...
    10. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathological, and genetic spectrum. Am J Surg Pathol 2007; 31: 1149-1160. Go to original source... Go to PubMed...
    11. Podhola M. Karcinom ledvin dospělých. Onkologie 2009; 3(2): 80-82.
    12. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2: 673-682. Go to original source... Go to PubMed...
    13. Hora M, Hes O, Eret V, et al. Translokační renální karcinom Xp11.2 typu ASPL/TFE3.Ces Urol 2008; 12(3): 186-193.
    14. Szakácsová, M. Nádory ledvin v Přehled novinek z 9. konference ESOU. Ces Urol 2012; 16(2): 130-136.
    15. Študentová H, Algoritmus léčby metastatického karcinomu ledviny. Urol. praxi, 2011; 12(3): 152-157.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.